1. Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
- Author
-
Christine Orr, Hai Ngu, Thomas Hunsaker, Daniel C. Kirouac, Melissa R. Junttila, Jacob Schwarz, Sheerin K. Shahidi-Latham, Xi Wang, Mark Merchant, Hartmut Koeppen, Jeffrey Eastham-Anderson, Marcia Belvin, Jocelyn Chan, Gabriele Schaefer, Marie-Claire Wagle, Peter M. Haverty, John Moffat, Stephanie J. Wang, Lily Shao, Shih-Min A. Huang, Margaret Solon, Jason H. Cheng, and Eva Lin
- Subjects
0301 basic medicine ,MAPK/ERK pathway ,Cell biology ,Cell signaling ,MAPK signaling cascades ,Signal Inhibition ,Mutant ,Cancer Treatment ,lcsh:Medicine ,Ras Signaling ,Signal transduction ,ERK signaling cascade ,Biology ,medicine.disease_cause ,Lung and Intrathoracic Tumors ,03 medical and health sciences ,In vivo ,Medicine and Health Sciences ,medicine ,Protein kinase A ,lcsh:Science ,Oncogenic Signaling ,Multidisciplinary ,Biology and life sciences ,MAP kinase kinase kinase ,lcsh:R ,Signaling cascades ,Cancers and Neoplasms ,Cancer ,medicine.disease ,Non-Small Cell Lung Cancer ,Blot ,030104 developmental biology ,Oncology ,Signal Processing ,Engineering and Technology ,lcsh:Q ,KRAS ,Research Article - Abstract
Mitogen-activated protein kinase (MAPK) pathway dysregulation is implicated in >30% of all cancers, rationalizing the development of RAF, MEK and ERK inhibitors. While BRAF and MEK inhibitors improve BRAF mutant melanoma patient outcomes, these inhibitors had limited success in other MAPK dysregulated tumors, with insufficient pathway suppression and likely pathway reactivation. In this study we show that inhibition of either MEK or ERK alone only transiently inhibits the MAPK pathway due to feedback reactivation. Simultaneous targeting of both MEK and ERK nodes results in deeper and more durable suppression of MAPK signaling that is not achievable with any dose of single agent, in tumors where feedback reactivation occurs. Strikingly, combined MEK and ERK inhibition is synergistic in RAS mutant models but only additive in BRAF mutant models where the RAF complex is dissociated from RAS and thus feedback productivity is disabled. We discovered that pathway reactivation in RAS mutant models occurs at the level of CRAF with combination treatment resulting in a markedly more active pool of CRAF. However, distinct from single node targeting, combining MEK and ERK inhibitor treatment effectively blocks the downstream signaling as assessed by transcriptional signatures and phospho-p90RSK. Importantly, these data reveal that MAPK pathway inhibitors whose activity is attenuated due to feedback reactivation can be rescued with sufficient inhibition by using a combination of MEK and ERK inhibitors. The MEK and ERK combination significantly suppresses MAPK pathway output and tumor growth in vivo to a greater extent than the maximum tolerated doses of single agents, and results in improved anti-tumor activity in multiple xenografts as well as in two Kras mutant genetically engineered mouse (GEM) models. Collectively, these data demonstrate that combined MEK and ERK inhibition is functionally unique, yielding greater than additive anti-tumor effects and elucidates a highly effective combination strategy in MAPK-dependent cancer, such as KRAS mutant tumors.
- Published
- 2017